# 21 CFR Part 203—Prescription drug marketing

21 CFR Part 203—Prescription drug marketing, “Prescription drug marketing”, is a CFR part of [21 CFR Chapter I, Subchapter C—DRUGS: GENERAL](https://ontology.bommaritollc.com/id/01a0f094-b59c-71c5-9205-607bcccd7551); it is made under 9 laws; in force.

IRI: <https://ontology.bommaritollc.com/id/01a0f094-b839-766e-835b-db421d00a97c>

Within: [Title 21—Food and Drugs](https://ontology.bommaritollc.com/id/01a0f094-b437-7426-9a1d-f0a9f3d3e1aa) › [21 CFR Chapter I—FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES](https://ontology.bommaritollc.com/id/01a0f094-b455-74b7-9458-ed95d7b5ea58) › [21 CFR Chapter I, Subchapter C—DRUGS: GENERAL](https://ontology.bommaritollc.com/id/01a0f094-b59c-71c5-9205-607bcccd7551)

Type: [schema:Legislation](https://schema.org/Legislation)

- `adms:identifier`: [cfr-part 21 CFR Part 203](https://ontology.bommaritollc.com/id/01a0f094-b83a-75e0-8379-a148e5c64064)
- **authority note** (`bcleg:authorityNote`): 21 U.S.C. 331, 333, 351, 352, 353, 360, 371, 374, 381.
- `eli:based_on`:
  - [21 U.S.C. 331 Prohibited acts](https://ontology.bommaritollc.com/id/01a0f06c-cc92-7163-972f-ca345be44724)
  - [21 U.S.C. 333 Penalties](https://ontology.bommaritollc.com/id/01a0f06c-cc94-755b-ac0a-08633bef7d10)
  - [21 U.S.C. 351 Adulterated drugs and devices](https://ontology.bommaritollc.com/id/01a0f06c-ccc8-7536-94e4-d8e798dad75a)
  - [21 U.S.C. 352 Misbranded drugs and devices](https://ontology.bommaritollc.com/id/01a0f06c-ccca-77a6-a36b-8f6a7374070e)
  - [21 U.S.C. 353 Exemptions and consideration for certain drugs, devices, and biological products](https://ontology.bommaritollc.com/id/01a0f06c-cccb-7545-90e2-a1651be32192)
  - [21 U.S.C. 360 Registration of producers of drugs or devices](https://ontology.bommaritollc.com/id/01a0f06c-ccfb-75a5-8f8d-2899cf8ac727)
  - [21 U.S.C. 371 Regulations and hearings](https://ontology.bommaritollc.com/id/01a0f06c-cd7f-7552-9512-d5162892046d)
  - [21 U.S.C. 374 Inspection](https://ontology.bommaritollc.com/id/01a0f06c-cd83-7175-9624-79d9d7728390)
  - [21 U.S.C. 381 Imports and exports](https://ontology.bommaritollc.com/id/01a0f06c-cdf5-70c8-b8d2-b17f8ad341e4)
- `prov:wasDerivedFrom`:
  - [evidence from https://www.govinfo.gov/app/details/CFR-2025-title21-vol4](https://ontology.bommaritollc.com/id/01a0f094-b839-766e-835b-db419329c4f0)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f094-da1b-7773-a574-88eb6a6ecfe6)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f0cf-7d3c-734e-b89f-679d6bb13de2)
  - [evidence from https://www.govinfo.gov/link/cfr/21/203?year=mostrecent&link-type=details](https://ontology.bommaritollc.com/id/01a10f16-3eba-7430-bad3-f740f436587e)
- `schema:isPartOf`: [21 CFR Chapter I, Subchapter C—DRUGS: GENERAL](https://ontology.bommaritollc.com/id/01a0f094-b59c-71c5-9205-607bcccd7551)
- `schema:legislationIdentifier`: 21 CFR Part 203
- `schema:legislationJurisdiction`: [United States](https://ontology.bommaritollc.com/id/01a0ed8e-f797-7004-b7f5-bec2695977c0)
- `schema:legislationLegalForce`: [schema:InForce](https://schema.org/InForce)
- `schema:legislationType`: [CFR part](https://ontology.bommaritollc.com/vocab/leg/cfrPart)
- `schema:name`: Prescription drug marketing
- `schema:url`: [https://www.govinfo.gov/link/cfr/21/203?year=mostrecent&link-type=details](https://www.govinfo.gov/link/cfr/21/203?year=mostrecent&link-type=details)
- `skos:prefLabel`: 21 CFR Part 203—Prescription drug marketing
- **source note** (`bcleg:sourceNote`): 64 FR 67756, Dec. 3, 1999, unless otherwise noted.

## Elsewhere

- [Official page](https://www.govinfo.gov/link/cfr/21/203?year=mostrecent&link-type=details) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/CFR-2025-title21-vol4) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/) (www.govinfo.gov)

## Pointing here

- Parts (7; `schema:isPartOf`):
  - [21 CFR Part 203, Subpart A—General Provisions](https://ontology.bommaritollc.com/id/01a0f094-b5ab-7088-8bcc-8c443b9970dc)
  - [21 CFR Part 203, Subpart B—Reimportation](https://ontology.bommaritollc.com/id/01a0f094-b5ac-7792-9cbe-2986b4f1c45d)
  - [21 CFR Part 203, Subpart C—Sales Restrictions](https://ontology.bommaritollc.com/id/01a0f094-b5ad-7158-a794-c25a9d1cf3be)
  - [21 CFR Part 203, Subpart D—Samples](https://ontology.bommaritollc.com/id/01a0f094-b5ad-7158-a794-c267721798e7)
  - [21 CFR Part 203, Subpart E—Wholesale Distribution](https://ontology.bommaritollc.com/id/01a0f094-b5ae-7353-9683-dd1b0e9264c0)
  - [21 CFR Part 203, Subpart F—Request and Receipt Forms, Reports, and Records](https://ontology.bommaritollc.com/id/01a0f094-b5af-742d-99ba-2064fb809841)
  - [21 CFR Part 203, Subpart G—Rewards](https://ontology.bommaritollc.com/id/01a0f094-b5b0-7521-aea2-73789364ea54)

---
Also as: [Turtle](https://ontology.bommaritollc.com/id/01a0f094-b839-766e-835b-db421d00a97c.ttl), [JSON-LD](https://ontology.bommaritollc.com/id/01a0f094-b839-766e-835b-db421d00a97c.jsonld), [N-Triples](https://ontology.bommaritollc.com/id/01a0f094-b839-766e-835b-db421d00a97c.nt), [HTML](https://ontology.bommaritollc.com/id/01a0f094-b839-766e-835b-db421d00a97c)
Cite as: 21 CFR Part 203—Prescription drug marketing. bc-ontology, release 0.1.0-rc38, 2026-10-21. https://ontology.bommaritollc.com/id/01a0f094-b839-766e-835b-db421d00a97c
Release 0.1.0-rc38, graph hash 05350a11cf9d0c42fba51e92b877115781ab65cb92afcd6b172ff9f8f4abf0bd.
